The generic name of Medoxomil is Dobasic Acid Tablets, and Silegilan enhances the effect of Dobasic Acid Tablets, and the combination of the two is more appropriate for stable control of the disease. Silegiran can be used in early Parkinson’s disease alone or in combination with or with levodopa and peripheral dopa decarboxylase inhibitors. The most common adverse effects of this product include upright hypotension, nausea, dry mouth, and vertigo, and it is contraindicated in people who are allergic to this product, or in patients with active gastric or duodenal ulcers. Dobasic hydrazide tablets are a combination preparation containing levodopa and benserazide and are used in the treatment of Parkinson’s disease and symptomatic Parkinson’s syndrome. Adverse effects of this product include insomnia, anxiety, cardiac arrhythmia, nausea, vomiting, etc. It is contraindicated for those who are allergic to this product, women during pregnancy, and patients under 25 years of age. The combination of Silegiran and Dobasic Hydrazide Tablets can smoothly control the condition of Parkinson’s patients, and the efficacy is better. However, it is necessary to pay attention to reduce the dosage of dobasic hydrazide tablets when the two are used together, which can reduce the occurrence of side effects. It is recommended to use the drug under the guidance of a doctor, and if discomfort occurs after the administration of the drug, please consult your physician promptly.